952 related articles for article (PubMed ID: 29599329)
21. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
22. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
[TBL] [Abstract][Full Text] [Related]
23. Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.
Reynders A; Brouckaert O; Smeets A; Laenen A; Yoshihara E; Persyn F; Floris G; Leunen K; Amant F; Soens J; Van Ongeval C; Moerman P; Vergote I; Christiaens MR; Staelens G; Van Eygen K; Vanneste A; Van Dam P; Colpaert C; Neven P
Breast; 2014 Aug; 23(4):453-9. PubMed ID: 24768478
[TBL] [Abstract][Full Text] [Related]
24. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Kuwano H
Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for additional non-sentinel lymph node involvement in breast cancer patients with one positive sentinel node.
Meattini I; Saieva C; Bertocci S; Francolini G; Zei G; De Luca Cardillo C; Scotti V; Greto D; Bonomo P; Orzalesi L; Bianchi S; Livi L
Tumori; 2015; 101(1):78-83. PubMed ID: 25702658
[TBL] [Abstract][Full Text] [Related]
27. A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes.
Canavese G; Bruzzi P; Catturich A; Vecchio C; Tomei D; Del Mastro L; Carli F; Guenzi M; Lacopo F; Dozin B
Eur J Surg Oncol; 2014 Jul; 40(7):835-42. PubMed ID: 24684810
[TBL] [Abstract][Full Text] [Related]
28. Lymphovascular invasion is a significant risk factor for non-sentinel nodal metastasis in breast cancer patients with sentinel lymph node (SLN)-positive breast cancer: a cross-sectional study.
Wei C; Deng Y; Wei S; Huang Z; Xie Y; Xu J; Dong L; Zou Q; Yang J
World J Surg Oncol; 2023 Dec; 21(1):386. PubMed ID: 38097994
[TBL] [Abstract][Full Text] [Related]
29. Positive non-sentinel axillary lymph nodes in breast cancer with 1-2 sentinel lymph node metastases.
Zheng J; Cai S; Song H; Wang Y; Han X; Wu H; Gao Z; Qiu F
Medicine (Baltimore); 2018 Nov; 97(44):e13015. PubMed ID: 30383658
[TBL] [Abstract][Full Text] [Related]
30. Factors predicting the non-sentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases.
Boler DE; Uras C; Ince U; Cabioglu N
Breast; 2012 Aug; 21(4):518-23. PubMed ID: 22410110
[TBL] [Abstract][Full Text] [Related]
31. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer.
Akay CL; Albarracin C; Torstenson T; Bassett R; Mittendorf EA; Yi M; Kuerer HM; Babiera GV; Bedrosian I; Hunt KK; Hwang RF
Breast J; 2018 Jan; 24(1):28-34. PubMed ID: 28608612
[TBL] [Abstract][Full Text] [Related]
32. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?
Sávolt A; Polgár C; Musonda P; Mátrai Z; Rényi-Vámos F; Tóth L; Kásler M; Péley G
Clin Breast Cancer; 2013 Oct; 13(5):364-70. PubMed ID: 23773380
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.
Mittendorf EA; Hunt KK; Boughey JC; Bassett R; Degnim AC; Harrell R; Yi M; Meric-Bernstam F; Ross MI; Babiera GV; Kuerer HM; Hwang RF
Ann Surg; 2012 Jan; 255(1):109-15. PubMed ID: 22167004
[TBL] [Abstract][Full Text] [Related]
34. The characteristics of the sentinel lymph node metastasis in predicting the axillary lymph node status in patients with breast carcinoma.
Olszewski WP; Szumera-Ciećkiewicz A; Piechocki J; Towpik E; Olszewski WT
Pol J Pathol; 2009; 60(3):138-43. PubMed ID: 20069508
[TBL] [Abstract][Full Text] [Related]
35. Factors predicting non-sentinel lymph node metastasis in T1-2 invasive breast cancer with 1-2 axillary sentinel lymph node metastases: Presentation of Ondokuz Mayis scoring system.
Kuru B; Sullu Y; Yuruker S; Koray Bayrak I; Ozen N
J BUON; 2016; 21(5):1129-1136. PubMed ID: 27837614
[TBL] [Abstract][Full Text] [Related]
36. Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasis.
Travagli JP; Atallah D; Mathieu MC; Rochard F; Camatte S; Lumbroso J; Garbay JR; Rouzier R
Eur J Surg Oncol; 2003 May; 29(4):403-6. PubMed ID: 12711299
[TBL] [Abstract][Full Text] [Related]
37. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
38. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
40. [A nomogram to predict non-sentinel lymph node metastasis for breast cancer patients with positive axillary sentinel lymph node].
Yang ZB; Huang Z; Wang SL; Tang Y; Jing H; Wang JY; Zhang JH; Yang Y; Song YW; Fang H; Jin J; Liu YP; Qi SN; Li N; Tang Y; Lu NN; Chen B; Wang X; Gao JD; Wang J; Xuan LX; Fang Y; Li YX
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):653-659. PubMed ID: 32867457
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
